论文部分内容阅读
根据卫生部药政发（94）第530号文精神及卫生部（93）S－59号新生物制品批件要求，由广州市卫生防疫站、中国药品生物制品检定所等单位对卫生部生物制品总公司协作组、长春等5个生研所试生产的吸附精制百白破混合制剂（APDT）进行了回期临床反应观察。旨在通过本次大规模的婴幼
According to the spirit of Ministry of Health Pharmaceutical issued 94 (94) and the spirit of the Ministry of Health (93) S-59 approval of new biological products requirements, by the Guangzhou Municipal Health and Epidemic Prevention Station, China Pharmaceutical and Biological Products Inspection and other units of the Ministry of Health biological products Head Office Collaboration Group, Changchun and other 5 Institute of Biostatistically absorbed by the trial production of Bletilla striata mixed formulations (APDT) for the clinical response to the observation. Designed to pass this massive infancy